CRECON MEDICAL ASSESSMENT

JP

Presentations

Presentation

  • Yamabe K, Hiroi S, Inoue S, Kobayashi M. Study on Cost-Effectiveness Analysis for Treatment of Major Depression Disease: A Systematic Review of Literature from 2004-2014. ISPOR 18th Annual European Congress, Milan, Italy. 7-11 November, 2015.

  • Yamabe K, Hiroi S, Inoue S, Kobayashi M. Study on Cost-Effectiveness Analysis for Ulcerative Colitis Treatment: A Systematic Review of Literature from 2004-2014. ISPOR 18th Annual European Congress, Milan, Italy. 7-11 November, 2015.

  • Yamabe K, Hiroi S, Inoue S, Kobayashi M. Study on Cost-Effectiveness Analysis for Multiple Myeloma Treatment:A Systematic Review of Literature from 2004-2014. ISPOR 18th Annual European Congress, Milan, Italy. 7-11 November, 2015.

  • Yamabe K, Inoue S, Hiroshima C. Epidemiology and Burden of Multiple Myeloma in Japan: A Systematic Review. ISPOR 18th Annual European Congress, Milan, Italy. 7-11 November, 2015.

  • Igarashi A, Fukuda T, Kobayashi M, Noto S, Saito S, Shimozuma K, Shiroiwa T, Ikeda S. Development of a national tariff for EQ-5D-5L in Japan. 32nd EuroQOL plenary meeting, Krakov, Poland. 10 Sep, 2015.

  • Okubo Y, Tsuruta D, Tang A, Inoue S, Chujyo K, Hagimori K, Otsuki M. Research about gap of treatment goals between doctors and psoriasis patients in Japan. The 30th Annual Meeting of the Japanese Society for Psoriasis Research. Sep 4-5, 2015.

  • Murata T, The investigation by the discrete choice experiment law on preference and willingness to pay of intermittent urinary catheters in patients with dysuria caused by neurogenic bladder. ISPOR Japan Chapter 11th Annual Meeting, Tokyo, Japan. 30th August, 2015. (in Japanese)

  • Ikeda S, Inoue S, Kobayashi M. Cost-effectiveness Analysis of Condoliase in Patients with Lumber Disc Herniation in Japan. ISPOR 20th Annual International Meeting, May 16-20 2015, Philadelphia, PA, USA

  • Sugimoto T, Kamae I, Yamabe K, Kobayashi M. Assessing the quality of health economic evaluations published in a Japanese setting: a systematic review of the literature for 1991-2012. ISPOR 20th Annual International Meeting. May 16-20, 2015, Philadelphia, PA, USA.

  • Kobayashi M. The actual techniques of modelling analysis in Japan. Center for Health Economics & QOL Research, Niigata University of Health and Welfare. Niigata, Japan.21th Feb, 2015. (in Japanese)

TOPPresentation
TOP
費用対効果分析

Cost-effectiveness analysis

To evaluate the cost-effectiveness of pharmaceuticals and medical devices by pharmacoeconomics (medical economic assessment), many specialized technologies and knowledge should be combined. We evaluate the cost-effectiveness of medical technologies using advanced modeling and statistical analysis technologies that we have developed over many years.

  • Cost-effectiveness analysis
  • Decision-making model construction
  • Review of previous studies
  • Systematic review
  • Indirect comparison/
    network meta-analysis
  • Budget impact analysis
    in the introduction of new pharmaceuticals
疾病負担分析

Burden of illness analysis

The socio-economic burden of disease is correlated with the therapeutic value of the disease. However, the estimation of such disease burdens is hardly done. We conduct burden of illness analysis to estimate epidemiological parameters, including the numbers of patients and events, long-term survival rates, and medical expenses.

  • Quantification of a target disease’s
    financial burden
  • Estimation and prediction of the number of patients
  • Estimation of lifetime medical expenses
  • Estimation of expected survival time
リアルワールドデータ

Real-world data/
Patient outcome data analyses

Real-world data, such as medical and receipt data, and patient outcome data are analyzed based on advanced statistical knowledge and technology.

  • Planning of survey/
    Development of protocols
  • Medical data analysis
  • Claims data analysis
  • QOL survey
  • Conjoint analysis/
    Discrete choice experiment (DCE)
  • Exploratory analysis
教育及び各種コンサルティング

Education
and other consulting services

We support in-house educational and enlightenment activities related to pharmacoeconomics (medical economic assessment) and health technology assessment (HTA), and provide consulting services. Furthermore, we provide consulting services based on review and summarization of technology appraisal (TA) by the UK’s National Institute for Health and Clinical Excellence (NICE).

  • Lecture/Workshop
  • Other consulting services
  • Review of NICE TA